 |
|
End-of-Life Practices in European Intensive Care Units
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: Dr Sprung and colleagues1 stated that "active shortening of the dying process" was rare in their sample and affected only 2% of patients who died after life-sustaining treatment was withheld or withdrawn.
A recent European survey,2 on the other hand, has indicated that 40% of ICU physicians admitted that they sometimes administered drugs to hasten death. Likewise, physicians at neonatal ICUs in 2 European countries admitted with significant frequency (in France, 73% of respondents; in the Netherlands, 47%) that they had decided to administer drugs with the purpose of ending the patient's life.3 In Italy, a survey found that the deliberate use of lethal doses of drugs was admitted by about 4% of ICU physicians and was considered ethically acceptable by about 16%.4
Although prospective studies cannot be compared with questionnaire-based surveys, overall these results imply that this practice in not as uncommon as Sprung et al . . . [Full Text of this Article]
Alberto Giannini, MD
Department of Anaesthesia and Intensive Care
Istituti Clinici di Perfezionamento
Milan, Italy
RELATED ARTICLES
End-of-Life Practices in European Intensive Care Units
Erwin J. O. Kompanje
JAMA. 2003;290(22):2938-2939.
EXTRACT
| FULL TEXT
End-of-Life Practices in European Intensive Care Units—Reply
Charles L. Sprung, Peter Sjokvist, Seppo Hovilehto, and Elisabet Wennberg
JAMA. 2003;290(22):2939-2940.
EXTRACT
| FULL TEXT
End-of-Life Practices in European Intensive Care Units: The Ethicus Study
Charles L. Sprung, Simon L. Cohen, Peter Sjokvist, Mario Baras, Hans-Henrik Bulow, Seppo Hovilehto, Didier Ledoux, Anne Lippert, Paulo Maia, Dermot Phelan, Wolfgang Schobersberger, Elisabet Wennberg, and Tom Woodcock
JAMA. 2003;290(6):790-797.
ABSTRACT
| FULL TEXT
|
